Thalidomide in the treatment of myelodysplastic syndrome with fibrosis

Leukemia Research

Volumn 26, Issue 10, 2002, Pages 965-966

  Tsirigotis, Panagiotis ^a   Venetis, Evangelos ^a   Rontogianni, Dimitra ^b   Dervenoulas, John ^b   Kontopidou, Flora ^a   Apostolidis, Panos ^a  

^a Social Insurance Foundation   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Fibrosis; Myelodysplastic syndrome; Thalidomide; Treatment

Indexed keywords

ERYTHROPOIETIN; THALIDOMIDE;

AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG ACTIVITY; FEMALE; FIBROSIS; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOMA; PANCYTOPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; BONE MARROW; FEMALE; FIBROSIS; HUMANS; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0036348566     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00036-X     Document Type: Article

References (5)

1. A patient oriented approach to treatment of myelodysplastic syndromes
2. Allogeneic bone marrow transplantation for myelodysplastic syndromes: Outcome analysis according to IPSS score
3. Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies
4. Thalidomide in dermatology: New indications for an old drug
5. Pharmacology of thalidomide